|
| | 
|
 | |
         
|  |
|  |
|
Mostrar Noticias: Ver noticias de otros activosBúsqueda de noticias relacionadas a la acción Amylin Pharmaceut (ordenadas por fecha):
|
Allscripts sued by shareholder, seeks proxy fightReutersBillionaire investor Carl Icahn scored a victory with a similar lawsuit last month in his push to have Amylin Pharmaceuticals (AMLN.O) put up for sale. Icahn sued the company in the same Delaware court, arguing Amylin's similar advance notice bylaws ...y más » |
|
Did You Buy These Stocks?NASDAQShares of Amylin Pharmaceuticals Inc. (AMLN) were trading around $10 when we alerted readers to the stock last December, and based on Tuesday's closing price of $26.69, it is up nearly 155%. The stock touched a 52-week high of $28.02 on May 16, 2012.y más » |
|
Amylin Pharmaceuticals (AMLN) - Daily Volume UpdateAVAFINShares of Amylin Pharmaceuticals rose $1.65 (+6.43%) to $27.30 in today's trading session. The price of AMLN ranged between $26.65 - $27.40. Volume is 8M in relation to the three month average volume of 4M shares. AMLN is trading above the 50 day ... |
|
Amylin Said to Attract Interest From Pfizer, AstraZenecaBloombergDeals Amylin Said to Attract Pfizer, AstraZeneca, Sanofi in Sale Amylin Pharmaceuticals Inc. (AMLN) has lured suitors such as Pfizer Inc., AstraZeneca Plc and Sanofi (SAN), which signed confidentiality agreements on the drugmaker's sale process, ...y más » |
|
Our Take: CSOD, VOXX, FSLR, VRX Among Charts to WatchThe Mumbai TimesAmylin Pharmaceuticals Inc (NASDAQ:AMLN) shares were trading at $27.30 while reporting up 6.43% from yesterdays close. The 13 analysts offering 12-month price forecasts for Amylin Pharmaceuticals Inc have a median target of 22.00, with a high estimate ... |
|
Wider Loss at AmylinZacks.comAmylin Pharmaceuticals (AMLN - Analyst Report) reported a first quarter loss of 58 cents per share, wider than the year-ago loss of 24 cents. First quarter revenues, which increased 0.6% to $153.7 million, were well below the Zacks Consensus Estimate ...y más » |
|
Amylin Pharmaceuticals To Present At Annual Meeting Of StockholdersTheStreet.com (press release)By Business Wire 05/08/12 - 04:15 PM EDT Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Annual Meeting of Stockholders on Tuesday, May 15, 2012 at 9:00 am PT/ 12:00 pm ET from the Company's corporate headquarters in San Diego. |
|
Tuesday's biggest gaining and declining stocksMarketWatchAmylin Pharmaceuticals Inc. (NASDAQ:AMLN) shares tacked on 6%. The company said in a filing late Monday that one of its directors had bought 18000 shares of the firm's stock. There's no legal provision in EU treaties for a country to exit the euro ...y más » |
|
M&A: Four Health Care Stocks in Play (AMLN, FRX, STJ, EW)Stock Traders DailyAfter Carl Icahn turned up the heat on Amylin Pharmaceuticals (Nasdaq: AMLN) it became apparent that this company will ultimately have to sell itself. Amylin spurned an unsolicited offer from Bristol-Myers Squibb (NYSE: BMY) in late March.y más » |
|
The Definitive Biotech ETF Guide (IBB, XBI, FBT)MarketWatchFBT's top-10 holdings include Vertex Pharmaceuticals (NASDAQ:VRTX) , Incyte (NASDAQ:INCY) , Affymetrix (NASDAQ:AFFY) and Amylin Pharmaceuticals (NASDAQ:AMLN) , making it one of the more volatile ETF options in a sector known for its volatility.y más » |
|
Company News for May 16, 2012Zacks.com... surpassing the Zacks Consensus Estimate loss of $0.11 ? Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN - Analyst Report) rose 6.4%, a day after it announced that one of its directors had purchased 18000 shares of Amylin ? Shares of The TJX Companies, ...y más » |
|
Biotech targets fight back as Big Pharma circlesReutersFrom Amylin Pharmaceuticals (AMLN.O) to Onyx Pharmaceuticals (ONXX.O) and Human Genome Sciences (HGSI.O), these US-based companies are, on average, 60-percent held by their top 10 shareholders, according to ownership filings.y más » |
|
Pressure on premiums in M&A push biotech prices higherFierceBiotechBristol-Myers Squibb ($BMY) reportedly tried to tackle Amylin ($AMLN). But none of those deals have gone very far. And one--Roche's ($RHHBY) bid for Illumina ($ILMN)--collapsed when the sequencing company dug its heels in and demanded a better offer.y más » |
|
3 Stocks Near 52-Week Highs Worth SellingDailyFinanceAmylin Pharmaceuticals (NAS: AMLN) is dancing at a new high, with speculation fueled from Bloomberg that it is once again looking to be purchased. Its key drug, Bydureon, is a once-a-week injectable treatment for Type-2 diabetes that many potential ... |
|
What These Winning Investments Can Teach YouDailyFinanceAmylin (NAS: AMLN) has more than doubled on speculation that it would get a takeover bid after having its Bydureon diabetes drug approved, while Human Genome Sciences (NAS: HGSI) rebounded from huge losses last year after GlaxoSmithKline took a buyout ...y más » |
|
2012: Year of the dealmaker in biopharmaFierceBiotechThe surge of buyout stories recently--from Glaxo's ($GSK) move on Human Genome Sciences ($HGSI) to AstraZeneca's ($AZN) deal for Ardea ($RDEA) and the scuttlebutt about a try for Amylin ($AMLN)--has spotlighted just how hungry biopharma companies are ... |
|
MARKET TALK: Dick's To Increase Direct-Shipping OptionsWall Street Journal(min.zeng@dowjones.com) 12:44 (Dow Jones) Amylin Pharmaceuticals (AMLN) annual shareholder meeting is over and CEO Dan Bradbury made no mention of speculation drug maker is shopping itself around, as has been reported. Shareholders approved all items ...y más » |
|
amylin???????Leerink Swann?????Sanofi (NYSE:SNY) ?Merck (NYSE:MRK)??????Amylin Pharmaceuticals (NASDAQ:AMLN)??????????AMLN????6%???????????????????AMLN??????35? ...y más » |
|
Breaking News: 3 Dow Movers with News You Must KnowThe Mumbai TimesInc. (NYSE:MRK) is one of seven firms which have signed confidentiality agreements as part of Amylin's (NASDAQ:AMLN) acquisition process, says a Bloomberg report that cites unnamed sources. The latter's shares are jumping, as the firm is courted by ...y más » |
|
Top Gainers in Pre-market Today, May-15FyxnewsAmylin Pharmaceuticals Inc. (NASDAQ:AMLN) is currently trading at $26.74 up 4.3% in pre-market on 23500 shares traded. AMLN is trading 19.78% above its 50 day moving average and 82.09% above its 200 day moving average. AMLN is -4.54% below its 52-week ...y más » |
|
Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBloombergThe drugmaker is interested in buying San Diego-based Amylin Pharmaceuticals Inc. (AMLN) and its diabetes drugs Bydureon and Byetta, which generated more than $650 million in revenue last year, Bloomberg reported on May 15. Warner Chilcott Sues Watson ...y más » |
|
Anchura de la Página:
Imagen de Fondo: |
|  | |
|
|
